This publication does not concern the award of a public contract within the meaning of the Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1) is due to the specifications of the announcement form. This and the use of the medium “TED” does not involve any submission under procurement regulations whose validity is not mandatory by law or procurement regulations. It is a framework agreement with an option to join, which relates to various active substances.

The subject matter of the contract are medicinal products containing the active ingredient atovaquone.

The subject of the contract are drugs that contain the active ingredient loratadine.

The subject matter of the contract are medicinal products containing the active ingredient mercaptopurine.

The subject matter of the contract are medicinal products containing the active ingredient mesalazine in an oral dosage form.

The subject matter of the contract are medicinal products containing the active ingredient mesalazine in the dosage form rectal foam.

The subject matter of the contract are medicinal products containing the active ingredient mesalazine in the dosage form suppositories.

The subject matter of the contract are medicinal products containing the active ingredient olanzapine.

The subject matter of the contract are medicinal products containing the active ingredient permethrin.

The subject matter of the contract are medicinal products containing the active ingredient pipamperone.

The subject matter of the contract are medicinal products containing the active ingredient pyridostigminium cation in the dosage forms tablet and coated tablet.

The subject matter of the contract are medicinal products containing the active ingredient ranolazine.

The subject matter of the contract are medicinal products containing the active ingredient combination bimatoprost + timolol in an ophthalmological, non-divided dosage form.

The subject matter of the contract are medicinal products containing the active ingredient tacrolimus in the dosage forms prolonged-release tablet or granules for the preparation of a suspension for oral use.

The subject matter of the contract are medicinal products containing the active ingredient combination telmisartan + amlodipine.

The subject matter of the contract are medicinal products containing the active ingredient tranexamic acid in the dosage form film-coated tablet.

The subject matter of the contract are medicinal products containing the active ingredient triamcinolone acetonide in the dosage form cream.

The subject matter of the contract are medicinal products containing the active ingredient combination trifluridine + tipiracil.

The subject matter of the contract are medicinal products containing the active ingredient combination bimatoprost + timolol in an ophthalmological, divided dosage form.

The subject matter of the contract are medicinal products containing the active ingredient budesonide with the ATC code A07EA06.

The subject matter of the contract are medicinal products containing the active ingredient capsaicin in the dosage form patch (only prescription preparations).

The subject matter of the contract are medicinal products containing the active ingredient chlortalidone.

The subject of the contract are drugs that contain the active ingredient dornase alfa.

The subject matter of the contract are medicinal products containing the active ingredient everolimus with the ATC code L04AA18.

The subject of the contract are drugs that contain the active ingredient lidocaine in the form of plasters.